One-Year Outcome of Presbyopia Correction in Myopic and Hyperopic Ametropia With Monovision Approach in Surface Ablation

Sunday, April 19, 2015: 8:06 AM
Room 3 (San Diego Convention Center)
Erika N. Eskina, MD

To investigate the outcomes among presbyopic patients who underwent µ-monovision bi-aspheric multifocal PRK treatments with Mitomycin C.

Ongoing clinical study performed on 19 consecutive presbyopic patients (38 eyes), eight myopic and eleven hyperopic patients in age from 40 to 59 with SEQ from -6.50D to +4.25D and astigmatism up to 2D with surgical add from 1.75D to 2.25D. All presbyopic treatments were planned with Custom Ablation Manager software and ablations were performed using the SCHWIND AMARIS laser system (both SCHWIND eye-tech-solutions). Uncorrected distance and near visual acuities, refractive outcome, safety, corneal spherical aberration, and contrast sensitivity were recorded up to 12 months of follow up.

The myopic and hyperopic patients showed the SEq of -0.65±0.59D respectively -0.28±0.33D  in distance eye (DE) and -1.31±0.52D respectively -0.81±0.61D in near eye (NE). Binocular uncorrected visual acuity  was 0.1±0.1logMAR respectively 0.0±0.1logMAR for distance and 0.1±0.0logRAD respectively … 0.2±0.1logRAD for near. 75% of myopes and 73% of hyperopes achieved 0.1logMAR or better binocular uncorrected distance visual acuity (UDVA) and 0.2logRAD or better binocular uncorrected near visual acuity (UNVA). A significant change in corneal spherical aberration was seen. The average anisometropia  was 0.66D for myopic and 0.53D for hyperopic group. Contrast sensitivity slightly decreases at high spatial frequencies.

At 12 months postoperative, PresbyMAX µ-Monovision in PRK method showed us the safety with no loss in monocular distance corrected visual acuity in both distance and near eyes, and near spectacle independence in almost all cases with 91% in 0.2 logRAD.